Biodegradable, Drug‐Loaded Nanovectors via Direct Hydration as a New Platform for Cancer Therapeutics
Source abstract
Abstract
Abstract The stabilization and transport of low‐solubility drugs, by encapsulation in nanoscopic delivery vectors (nanovectors), is a key paradigm in nanomedicine. However, the problems of carrier toxicity, specificity, and producibility create a bottleneck in the development of new nanomedical technologies. Copolymeric nanoparticles are an excellent platform for nanovector engineering due to their structural versatility; however, conventional fabrication processes rely upon harmful chemicals that necessitate purification. In engineering a more robust (copolymeric) nanovector platform, it is necessary to reconsider the entire process from copolymer synthesis through self‐assembly and functionalization. To this end, a process is developed whereby biodegradable copolymers of poly(ethylene glycol)‐block‐poly(trimethylene carbonate), synthesized via organocatalyzed ring‐opening polymerization, undergo assembly into highly uniform, drug‐loaded micelles without the use of harmful solvents or the need for purification. The direct hydration methodology, employing oligo(ethylene glycol) as a nontoxic dispersant, facilitates rapid preparation of pristine, drug‐loaded nanovectors that require no further processing. This method is robust, fast, and scalable. Utilizing parthenolide, an exciting candidate for treatment of acute lymphoblastic leukemia (ALL), discrete nanovectors are generated that show strikingly low carrier toxicity and high levels of specific therapeutic efficacy against primary ALL cells (as compared to normal hematopoietic cells).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biomedical Engineering Eindhoven University of Technology P.O. Box 513 5600 MB Eindhoven The Netherlands
School of Cellular and Molecular Medicine University of Bristol Bristol BS8 1TD UK
Bristol Institute for Transfusion Sciences NHS Blood and Transplant Bristol BS34 7QH UK
Institute for Molecules and Materials Radboud University 6525 AJ Nijmegen The Netherlands
Department of Chemistry Swansea University Swansea SA2 8PP UK
Funding
Engineering and Physical Sciences Research Council · H2020 Marie Skłodowska-Curie Actions
References (63)
Show source-provided references
1. 10.1038/nnano.2008.11410.1038/nnano.2008.114 ↗
2. 10.1002/anie.20080258510.1002/anie.200802585 ↗
3. 10.1038/nrd259110.1038/nrd2591 ↗
4. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
5. 10.1517/17425247.2014.95056410.1517/17425247.2014.950564 ↗
6. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
7. 10.1016/j.addr.2012.09.03810.1016/j.addr.2012.09.038 ↗
8. 10.1111/cas.1296010.1111/cas.12960 ↗
9. 10.1002/wnan.136410.1002/wnan.1364 ↗
10. 10.1007/s11095-015-1784-110.1007/s11095-015-1784-1 ↗
11. 10.1016/j.progpolymsci.2016.05.00510.1016/j.progpolymsci.2016.05.005 ↗
12. 10.1039/c2cs35115c10.1039/c2cs35115c ↗
13. 10.1016/j.jconrel.2005.09.03410.1016/j.jconrel.2005.09.034 ↗
14. 10.1002/marc.20080071310.1002/marc.200800713 ↗
15. 10.1007/s10924-011-0317-110.1007/s10924-011-0317-1 ↗
16. 10.1016/j.progpolymsci.2011.06.00410.1016/j.progpolymsci.2011.06.004 ↗
17. 10.1039/C5BM00123D10.1039/C5BM00123D ↗
18. 10.1021/acs.chemrev.5b0034610.1021/acs.chemrev.5b00346 ↗
19. 10.1016/j.jconrel.2015.11.02110.1016/j.jconrel.2015.11.021 ↗
20. 10.1016/j.ejpb.2015.03.03310.1016/j.ejpb.2015.03.033 ↗
21. 10.1073/pnas.141149911110.1073/pnas.1411499111 ↗
22. 10.1166/jnn.2011.353610.1166/jnn.2011.3536 ↗
23. 10.1016/j.jconrel.2009.10.01410.1016/j.jconrel.2009.10.014 ↗
24. 10.1039/b818869f10.1039/b818869f ↗
25. 10.1007/s11095-008-9697-x10.1007/s11095-008-9697-x ↗
26. 10.1038/nmat234410.1038/nmat2344 ↗
27. 10.1073/pnas.080176310510.1073/pnas.0801763105 ↗
28. 10.1021/la900779t10.1021/la900779t ↗
29. 10.1039/C4PY01288G10.1039/C4PY01288G ↗
30. 10.1016/j.biomaterials.2005.09.01710.1016/j.biomaterials.2005.09.017 ↗
31. 10.1021/ma101461y10.1021/ma101461y ↗
32. 10.1021/cr068415b10.1021/cr068415b ↗
33. 10.1016/j.ijpharm.2011.08.05210.1016/j.ijpharm.2011.08.052 ↗
34. 10.1039/c3py01784b10.1039/c3py01784b ↗
35. 10.1056/NEJMra140097210.1056/NEJMra1400972 ↗
36. 10.1016/S0140-6736(12)62187-410.1016/S0140-6736(12)62187-4 ↗
37. 10.1111/j.1365-2354.2005.00513.x10.1111/j.1365-2354.2005.00513.x ↗
38. 10.1038/leu.2009.1210.1038/leu.2009.12 ↗
39. 10.1016/j.tetlet.2016.01.03910.1016/j.tetlet.2016.01.039 ↗
40. 10.1182/blood-2004-10-413510.1182/blood-2004-10-4135 ↗
41. 10.1074/jbc.M20384220010.1074/jbc.M203842200 ↗
42. 10.1038/sj.leu.240423010.1038/sj.leu.2404230 ↗
43. 10.1182/blood-2012-08-44885210.1182/blood-2012-08-448852 ↗
44. 10.1016/j.lfs.2004.01.02410.1016/j.lfs.2004.01.024 ↗
45. 10.1002/biof.552029010310.1002/biof.5520290103 ↗
46. 10.1038/nrd278110.1038/nrd2781 ↗
47. 10.1097/CAD.0b013e328356cad910.1097/CAD.0b013e328356cad9 ↗
48. 10.1021/mp200394t10.1021/mp200394t ↗
49. 10.4155/tde.11.15610.4155/tde.11.156 ↗
50. 10.1016/j.jconrel.2015.10.00510.1016/j.jconrel.2015.10.005 ↗
51. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
52. 10.1038/nbt.333010.1038/nbt.3330 ↗
53. 10.1016/j.jconrel.2017.02.03010.1016/j.jconrel.2017.02.030 ↗
54. 10.1021/acs.molpharmaceut.6b0100810.1021/acs.molpharmaceut.6b01008 ↗
55. 10.1007/s12195-015-0391-x10.1007/s12195-015-0391-x ↗
56. 10.1038/leu.2015.34310.1038/leu.2015.343 ↗
57. 10.1039/C4PY00863D10.1039/C4PY00863D ↗
58. 10.1021/acs.jmedchem.5b0091510.1021/acs.jmedchem.5b00915 ↗
59. 10.1021/mp400333310.1021/mp4003333 ↗
60. 10.1021/bm04970510.1021/bm049705 ↗
61. 10.1021/bm500468d10.1021/bm500468d ↗
62. 10.1074/jbc.M113.51117010.1074/jbc.M113.511170 ↗
63. 10.1016/S0076-6879(07)38006-310.1016/S0076-6879(07)38006-3 ↗